

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.*



**Yonghe Medical Group Co., Ltd.**

**雍禾醫療集團有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2279)**

### **SUPPLEMENTAL NOTICE OF ANNUAL GENERAL MEETING**

This notice is supplemental to the notice of the annual general meeting (the “**AGM**”) of Yonghe Medical Group Co., Ltd. dated April 30, 2024 (the “**Original AGM Notice**”) to convene the AGM which will be held at 2:00 p.m. on June 21, 2024 at Meeting Room, 4/F, China Nuclear E&C Building, 20 Ganluyuan Nanli, Chaoyang District, Beijing, PRC.

Details of the proposed resolutions to be considered at the AGM were stated in the Original AGM Notice. Unless otherwise stated, terms defined herein shall have the same meanings as those defined in the circular of the Company dated April 30, 2024 (the “**Circular**”). Apart from the amendments stated below, all the information contained in the Original AGM Notice remains to be valid and effective.

**SUPPLEMENTAL NOTICE IS HEREBY GIVEN** that the AGM will be held as originally scheduled. In addition, as set out in the supplemental circular of the Company dated June 3, 2024 (the “**Supplemental Circular**”), the resolutions under items numbered 8, 9, 10 and 11 stated in the Original AGM Notice should be deleted in their entirety and replaced by the following new resolutions under items numbered 8, 9, 10 and 11:

- A. To consider and pass (with or without amendments) the following ordinary resolutions of the Company as appropriate:

#### **ORDINARY RESOLUTIONS**

8. “**THAT:**

- (a) subject to paragraph (b) below, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to purchase its shares, subject to and in accordance with the applicable laws, be and is hereby generally and unconditionally approved;
- (b) the total shares of the Company to be purchased pursuant to the approval in paragraph (a) above shall not exceed 10% of the total issued shares of the Company (excluding any shares that are held as treasury shares) on the date of passing of this resolution and the said approval shall be limited accordingly;

- (c) for the purpose of this resolution, “Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:
  - i. the conclusion of the next annual general meeting of the Company;
  - ii. the revocation or variation of the authority given under this resolution by ordinary resolution passed by the Company’s shareholders in general meeting; and
  - iii. the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held.”

9. **“THAT:**

- (a) subject to paragraph (c) and (d) below, the exercise by the Directors during the Relevant Period (as defined below) of all the powers of the Company to allot, issue and deal with unissued shares of the Company (including any sale or transfer of shares of the Company out of treasury that are held as treasury shares) (which shall have the meaning ascribed to it under the Rules Governing the Listing of Securities on The Stock Exchange of the Hong Kong Limited coming into effect on June 11, 2024) and to make or grant offers, agreements and options might require the exercise of such powers be and is hereby generally and unconditionally authorized;
- (b) the approval in paragraph (a) above shall authorize the Directors to make or grant offers, agreements and options which would or might require the exercise of such powers after the end of the Relevant Period;
- (c) the shares allotted or agreed conditionally or unconditionally to be allotted (including any sale or transfer of shares of the Company out of treasury that are held as treasury shares) by the directors pursuant to the approval in paragraph (a) above, otherwise than pursuant to:
  - i. a Rights Issue (as defined below);
  - ii. the exercise of options under the share option scheme of the Company; and
  - iii. any scrip dividend scheme or similar arrangement providing for the allotment of shares in lieu of the whole or part of a dividend on shares of the Company in accordance with the articles of association of the Company;

shall not exceed 20% (If the Company performs share consolidation or spin-off after passing this resolution, adjustments are required) of the total issued shares of the Company (excluding any shares that are held as treasury shares) on the date of the passing of this resolution and the said approval shall be limited accordingly;

- (d) the authority conferred on the directors of the Company for all the powers of the Company to sell or transfer treasury shares pursuant to paragraph (a) shall only be exercised after the amendments to the Listing Rules relating to treasury shares has come into effect; and
- (e) for the purposes of this resolution:

“Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:

- (i) the conclusion of the next annual general meeting of the Company;
- (ii) the revocation or variation of the authority given under this resolution by ordinary resolution passed by the Company’s shareholders in general meeting; and
- (iii) the expiration of the period within which the next annual general meeting of the Company is required by the articles of association of the Company or any applicable laws to be held.

“Rights Issue” means an offer of shares open for a period fixed by the Directors to holders of shares of the Company or any class thereof on the register on a fixed record date in proportion to their then holdings of such shares or class thereof (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of any relevant jurisdiction or the requirements of any recognized regulatory body or any stock exchange).”

10. **“THAT:**

conditional upon the passing of the resolutions set out in items 8 and 9 of the notice convening this meeting (the **“Notice”**), the general mandate referred to in the resolution set out in item 9 of the Notice be and is hereby extended by the addition to the shares which may be allotted and issued or agreed conditionally or unconditionally to be allotted and issued (including any sale or transfer of shares out of treasury that are held as treasury shares) by the Directors pursuant to such general mandate of an amount representing the shares purchased by the Company pursuant to the mandate referred to in the resolution set out in item 8 of the Notice, provided that such amount shall not exceed 10% of the total issued shares of the Company (excluding any shares that are held as treasury shares) on the date of the passing of this resolution.”

- B. To consider and, if thought fit, pass with or without modification the following resolution as a special resolution:

**SPECIAL RESOLUTION**

11. **“THAT:**

the amendments to the memorandum and articles of association of the Company (the **“Memorandum and Articles of Association”**) set out in Appendix III to the Circular of the Company dated April 30, 2024 and Appendix I to the Supplemental Circular of the Company dated June 3, 2024 of which this notice forms part be and are hereby approved and the third amended and restated Memorandum and Articles of Association (a copy of which having been produced before the meeting and signed by the chairman of the meeting for the purpose of identification) be and is hereby adopted as the new Memorandum and Articles of Association.”

By Order of the Board  
**Yonghe Medical Group Co., Ltd.**  
**Zhang Yu**  
*Chairman*

June 3, 2024

*Notes:*

1. Please refer to the Original AGM Notice for details of other resolutions to be proposed at the AGM and other relevant matters.
2. Any shareholder of the Company entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and vote instead of him/her. A proxy needs not to be a member of the Company. If more than one proxy is so appointed, the appointment shall specify the number and class of shares in respect of which each such proxy is so appointed.
3. Since the form of proxy accompanying the circular of the Company dated April 30, 2024 does not reflect the revision of the general mandate to issue and repurchase shares proposed to be granted to the directors of the Company and proposed amendments to the Memorandum and Articles of Association in relation to the New Treasury Share Regime, a revised form of proxy (the “**Revised Form of Proxy**”) is enclosed for use at the AGM. For details, please refer to the section headed “Revised Form of Proxy” of this supplemental circular.
4. To be effective, a Revised Form of Proxy together with the power of attorney or other authority (if any), under which it is signed or a notorially certified copy of that power or authority, must be deposited at the Hong Kong branch share registrar of the Company, Tricor Investor Services Limited at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong not less than 48 hours (not later than 2:00 p.m. on June 19, 2024) before the time appointed for the holding of the AGM or any adjournment thereof. Delivery of the Revised Form of Proxy shall not preclude a shareholder of the Company from attending and voting in person at the AGM and, in such event, the instrument appointing a proxy shall be deemed to be revoked.
5. To ascertain shareholders’ eligibility to attend and vote at the AGM, the register of members of the Company will be closed from June 18, 2024 to June 21, 2024, both days inclusive, during which period no transfer of shares will be effected. In order to be eligible to attend and vote at the AGM, all share transfer documents accompanied by the relevant share certificates and other relevant documents, if any, must be lodged with Tricor Investor Services Limited, the Hong Kong branch share registrar of the Company, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, for registration not later than 4:30 p.m. on June 17, 2024.
6. All time and dates referred to in this notice refer to Hong Kong time and dates.

*As at the date of this notice, the executive directors of the Company are Mr. ZHANG Yu, Mr. ZHANG Hui and Ms. HAN Zhimei; the non-executive director of the Company is Mr. GENG Jiaqi and the independent non-executive directors of the Company are Ms. LIANG Jihong, Mr. CHAN Peng Kuan and Mr. LI Xiaopei.*